IV Iron Administration for Iron Deficiency Anemia

Introduction to IV Iron Therapy

The American Society of Hematology recommends administering ferric carboxymaltose (Ferinject) 750-1000 mg IV over 15 minutes as the preferred first-line option for iron deficiency anemia in India, or alternatively using iron sucrose 200 mg IV over 10 minutes (requiring multiple doses) 1, 2

Ferric carboxymaltose (FCM) is the optimal choice because it can deliver 750-1000 mg in a single 15-minute infusion, with no test dose required, and allows complete iron repletion in 1-2 visits, with an excellent safety profile and anaphylaxis risk <1:250,000 1, 2, 3
Iron sucrose is a widely available alternative in India, with a maximum dose of 200 mg per dose over 10 minutes, and no test dose required, but it requires 5-7 doses for complete repletion and has a lower cost but more hospital visits 1, 4

The Ganzoni formula can be used to calculate total iron deficit, which is body weight (kg) × [target Hb - actual Hb (g/dL)] × 0.24 + 500 mg, according to the American Journal of Hematology 3
The standard dosing approach is 1000-1500 mg total iron for patients ≥50 kg, and 15 mg/kg body weight for patients <50 kg, with an additional 500 mg beyond the calculated dose if Hb <7.0 g/dL, as recommended by the American Journal of Hematology 3

FCM can be given undiluted as a slow IV push or diluted up to 1000 mg in 250 mL normal saline, while iron sucrose should be diluted 200 mg in 100 mL normal saline, according to the American Journal of Hematology 1
The infusion protocol for FCM is 15 minutes, and for iron sucrose is 10 minutes, with resuscitation equipment immediately available for all IV iron administrations, as recommended by the Gut journal 1, 4

IV iron should not be given if there is an active bacterial infection present, or if there is a known anaphylaxis to the specific iron preparation, according to the Journal of the National Comprehensive Cancer Network 2, 5, 6
A test dose is mandatory for low molecular weight iron dextran (Infed) and for ferric gluconate or iron sucrose if the patient has drug allergies or previous iron sensitivity, as recommended by the American Journal of Hematology 1, 5, 6

An acceptable hematologic response is a hemoglobin increase ≥2 g/dL within 4 weeks, with more rapid rise with IV iron versus oral iron, according to the Praxis Medical Insights 3
The monitoring schedule should include rechecking hemoglobin, ferritin, and transferrin saturation at 4 weeks, and if the target is not achieved, investigating for ongoing blood loss or other causes, as recommended by the Gut journal and Praxis Medical Insights 3, 4

IV iron should not be given during active infection, and oral iron should not be used concurrently, as recommended by the Journal of the National Comprehensive Cancer Network and the American Journal of Hematology 1, 6
The most common adverse effects of IV iron are headache, dizziness, nausea, hypotension, and flushing during infusion, with true anaphylaxis being rare (<1%) with modern preparations, according to the Clinical Nutrition journal and the Gut journal 2, 4